A recent Clinical Evidence review examines the evidence for the effects of fetal cell or stem cell-derived therapy in people with Parkinson’s disease. Read the full systematic overview: http://clinicalevidence.bmj.com/x/systematic-review/1203/overview.html
Levodopa and dopamine agonists have been the mainstay of treatment for Parkinson’s disease, but side effects or drug effect wearing-off frequently develops. A more permanent and physiological approach would be to reconstruct the nigrostriatal pathways that are degenerated in Parkinson's disease, by transplanting new dopamine-producing cells.
In this podcast Arnar Astradsson, one of the authors of the review and consultant neurosurgeon at the Department of Neurorehabilitation, Traumatic Brain Injury Unit, Copenhagen University Hospital of Glostrup, discusses the clinical issues and evidence for this emerging treatment.
Disclaimer:
The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice and it is not intended to function as a substitute for a healthcare practitioner’s judgement, patient care or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast. Listeners should also be aware that professionals in the field may have different opinions.
By listening to this podcast, listeners agree not to use its content as the basis for their own medical treatment or for the medical treatment of others.
BMJ does not warrant the accuracy of the information contained in the podcast and to the fullest extent permitted by law, BMJ Publishing Group Limited is not responsible for any loss whatsoever resulting from the application of, or reliance upon, the information contained in this podcast.
